Lilly Sues Six Retatrutide Sellers — and the Legal Architecture Is the Story

First, the thing that governs everything below. A lawsuit is an allegation. Filing a complaint establishes nothing: no court has found any defendant liable, no defendant has been adjudged to have broken any law, and every allegation described here is a claim Lilly must still prove. Defendants have not yet answered. Nothing in this article should be read as a finding of wrongdoing by anyone named in it.

The six cases

All six were filed the same day. Four name sellers of research-use-only peptides, one names a med spa, and one names a compounding pharmacy:

• Eli Lilly & Co. v. Legendary Peptides, LLC, No. 1:26-cv-00347 (E.D. Tex.)
• Eli Lilly & Co. v. Lone Star Peptide Co. LLC, No. 4:26-cv-06562 (S.D. Tex.)
• Eli Lilly & Co. v. Texas Peptides Inc., No. 5:26-cv-05146 (W.D. Tex.)
• Eli Lilly & Co. v. Astra LLC d/b/a Astra Peptides, No. 5:26-cv-05147-FB (W.D. Tex.)
• Eli Lilly & Co. v. Aesthetic Envy Cosmetic Ctrs. LLC, No. 2:26-at-01347 (E.D. Cal.) — the med spa
• Eli Lilly & Co. v. Striker Pharmacy, LLC, No. 4:26-cv-06563 (S.D. Tex.) — the compounding pharmacy

Lilly seeks a permanent injunction against making, marketing, distributing, dispensing, or selling retatrutide; disgorgement of profits; and attorneys’ fees. Notably absent from that list is money damages as the centerpiece — the primary ask is to stop the conduct.

No patent claims. No FDCA claims. That is deliberate.

The complaints plead no patent infringement and no Federal Food, Drug, and Cosmetic Act counts. Instead they run almost entirely on state unfair-competition and consumer-protection statutes, drawn from eight states — Texas, Tennessee, Washington, North Carolina, South Carolina, Colorado, Connecticut, and Alaska — plus a single Lanham Act false-advertising count, pleaded against the med spa only.

Both omissions have straightforward explanations, and neither is an oversight.

The FDCA one is structural. The FDCA creates no private right of action. A competitor cannot walk into federal court and sue a rival directly for misbranding or for distributing an unapproved new drug; enforcement of those provisions belongs to the FDA and the Department of Justice. So a private litigant that wants a court to care about a defendant’s regulatory posture has to find a different vehicle. State consumer-protection statutes are that vehicle: they anchor liability in alleged deception of consumers rather than in regulatory noncompliance as such — while still putting the alleged noncompliance squarely in front of the judge as evidence.

The patent one is tactical. Asserting a patent in litigation invites the defendant to attack that patent’s validity, including through inter partes review at the Patent Trial and Appeal Board. Suing on state consumer-protection law instead keeps the patent estate out of the case entirely. Lilly gets to litigate the defendants’ conduct without putting its own intellectual property at risk in the process.

The doctrine to understand: an RUO label is not a legal shield

The single most portable idea in these filings, for anyone in this market, is that “for research use only” is a statement, not a safe harbor. Lilly’s theory looks past what a label says to the totality of the marketing conduct around the product, treating that conduct as evidence of what the product is actually intended for.

The kinds of things that theory points at are the ordinary furniture of consumer-facing sales: dosing charts, injection instructions, weight-loss claims, administration in a clinical or aesthetic setting, and distribution through channels aimed at consumers rather than laboratories. The argument is that a disclaimer does not neutralize the rest of the page. Whether any particular defendant did any of this is exactly what has yet to be established — but the legal proposition does not depend on the outcome of these six cases, and it is the proposition worth internalizing.

Why retatrutide is different from the 2024–25 compounding fights

These suits are different in kind from the semaglutide and tirzepatide compounding litigation that preceded them, and the reason is regulatory status.

Retatrutide is investigational. It is in Phase 3 trials and has no approved status anywhere in the world. That single fact removes the gray zone the earlier disputes were fought in. Semaglutide and tirzepatide were, at the relevant times, approved drugs in shortage — and shortage status opens a compounding pathway that would otherwise be closed. The fight there was about the boundaries of a real exception. For retatrutide there is no approved version, so no shortage pathway has ever applied, and no compounding exception is available to argue about. There is no lawful compounding lane to be inside of.

A related case, still pending. In Eli Lilly & Co. v. Kennedy, No. 1:24-cv-01503 (S.D. Ind.), Lilly challenged the FDA’s March 2024 decision to classify retatrutide as a drug rather than a biological product. In an amended order of October 3, 2025, the district court upheld the FDA on one question and not the other. It held that the FDA’s regulation “unambiguously requires that proteins contain at least forty-one alpha amino acids,” so the FDA did not violate its own regulation in declining to designate retatrutide a protein. It held the FDA’s reasoning that retatrutide is not “analogous” to a protein arbitrary and capricious, and vacated “that portion of the agency’s decision.” The court did not order the FDA to classify retatrutide as a biologic; it said there is a “meaningful possibility that the agency could lawfully reach the same conclusion.” Its final judgment of December 16, 2025 “VACATES the agency’s designation decision and REMANDS to the agency for further proceedings on Plaintiff’s ‘analogous’ products claim.” Lilly appealed to the Seventh Circuit in February 2026. Lilly’s complaint in that case states that biological products “are ineligible for exemptions for compounded drugs” under 21 U.S.C. §§ 353a and 353b. The appeal is covered in Lilly v. Kennedy: Whether Retatrutide Is a Drug or a Biologic Goes to the Seventh Circuit.

Six lawsuits are the visible part

In its own announcement, Lilly said it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement, and professional licensing boards, and that it has flagged more than 14,000 websites, advertisements, social-media posts, and product listings across more than 100 countries to internet service providers, platforms, and e-commerce companies. It publicly called on social-media platforms, payment processors, shipping carriers, and regulators to cut off the infrastructure that it says enables these sales.

That is the part with the wider reach. Litigation names six defendants; a payment processor or a marketplace changing a policy touches everyone on it at once, without any court ruling on anything.

Where this sits on the map

Our three-lanes explainer sorted peptide access into FDA-approved drugs (Lane 1), compoundable peptides in the 503A channel (Lane 2), and research-use-only peptides (Lane 3). Every regulatory action described there was an FDA action landing in Lane 1 or Lane 2.

This is the structural novelty: a private litigant acting in Lane 3. Not a regulator, not a referral, not a warning letter — a competitor filing suit and naming research-supply sellers as defendants. Lane 3 was never outside the reach of law; it has simply not been the subject of a named private lawsuit before. That extends the earlier map rather than contradicting it: the lanes still describe distinct regulatory channels, and what changed is who is willing to litigate in one of them, not what the FDA has decided about it.

What this is, and isn’t

This is litigation reporting. Six complaints have been filed; none has been answered, tried, or decided. Nothing here establishes that any defendant did anything wrong, and nothing here predicts how any of these cases will come out — a state consumer-protection theory of this shape has not been tested against this particular set of facts, and we will not guess at the result. Neither the filings nor this article is a safety, efficacy, or approval determination about retatrutide or any other compound, and nothing here is a dosing or usage recommendation. Retatrutide is investigational and is not approved for human use anywhere. This is not legal advice. We will update as the dockets move.

Sources

• Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (Eli Lilly and Company, Aug 12, 2026) — primary, the plaintiff’s own announcement: the six filings, the 200+ referrals, the 14,000+ listings across 100+ countries, and retatrutide’s investigational status.
• Lilly Retatrutide Lawsuits Target RUO Peptide Sellers (Frier Levitt) — secondary legal analysis, attributed, for the case captions and numbers, the eight-state pleading, the absence of patent and FDCA counts and the reasons for it, the relief sought, and the “RUO label is not a legal shield” doctrine.
• Amended Order on Cross-Motions for Summary Judgment, Eli Lilly & Co. v. Kennedy, No. 1:24-cv-01503 (S.D. Ind. Oct. 3, 2025) and Order and Final Judgment (S.D. Ind. Dec. 16, 2025) — primary, via the RECAP archive: the district court’s holdings on “protein” and “analogous product,” the vacatur and remand, and the absence of any order to reclassify.
• Complaint, Eli Lilly & Co. v. Kennedy, No. 1:24-cv-01503 (S.D. Ind. Sept. 3, 2024) — primary: Lilly’s statement that biological products are ineligible for the compounding exemptions.
• Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide (BioPharma Dive) — secondary trade press, for the filing date and the composition of the defendant set.
• Eli Lilly files lawsuits against six companies for allegedly selling retatrutide (Healio) — secondary trade press, corroborating the defendant list and the allegations as allegations.